Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-mFBG for Imaging Myocardial Sympathetic Innervation in Heart Failure
NCT06965621Phase 2Recruiting
- Sponsor
- Innervate Radiopharmaceuticals
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of florbenguane F-18 in heart failure (HF) and ischemic cardiomyopathy (ICM) (2 arms), sponsored by Innervate Radiopharmaceuticals. Primary endpoint: Degree of reduced myocardial 18F-mFBG uptake at 24 hours. Started Nov 2025; status: recruiting.
02
Drugs
florbenguane F-18
03
Conditions
heart failure (HF)ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT06965621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965621.